Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOZART: Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma
NCT06492837Phase 2Active, not recruiting
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Oct 2024
- Primary completion
- Sep 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 2
01
Overview
A Phase 2 trial of mosunetuzumab, zanubrutinib in follicular lymphoma (FL), sponsored by Fondazione Italiana Linfomi. Started Oct 2024; status: active, not recruiting.
02
Drugs
mosunetuzumabzanubrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06492837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492837.